Treatment of Skin and Soft Tissue Infections

Adolf W. Karchmer

doi:10.1128/9781555817817.ch19

Chapter 19 : Treatment of Skin and Soft Tissue Infections

VIEW AFFILIATIONS HIDE AFFILIATIONS

Affiliations: 1: Division of Infectious Diseases, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Kennedy-6A, Boston, MA 02215

Content Type: Monograph

Publication Year: 2003

Category: Clinical Microbiology

Book DOI: 10.1128/9781555817817

Chapter DOI: 10.1128/9781555817817.ch19

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:

Treatment of Skin and Soft Tissue Infections, Page 1 of 2

< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap19-1.gif /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap19-2.gif

Abstract:

Bacterial infections of the skin, which often extend to involve adjacent soft tissue, have been classified as primary pyodermas, infectious gangrene and gangrenous cellulitis, and secondary bacterial infections complicating preexisting skin lesions. The major pathogens causing primary skin infection and soft tissue infection among immunocompetent patients, in the absence of unique epidemiologic considerations, are Staphylococcus aureus and beta-hemolytic streptococci, particularly Streptococcus pyogenes. Surveillance programs (SENTRY Antimicrobial Surveillance Program) that have examined the microbiology of nosocomial or community-acquired skin and soft tissue infections occurring in hospitalized patients also indicate differences in the causes of the infections compared with those associated with the primary pyodermas. Polymicrobial infections in the feet of patients with diabetes mellitus (so called "diabetic foot infection") usually arise from neuropathic ulcers and frequently occur in the setting of arterial insufficiency. Although patients with these infections are often included in treatment trials for complicated skin and soft tissue infections, because of the uniqueness of the clinical setting and the frequency of this problem some studies have focused solely on fluoroquinolone treatment of this entity. Data from comparative and noncomparative clinical trials demonstrate that currently available fluoroquinolones are highly effective treatment for mild, uncomplicated as well as for more severe, complicated skin and soft tissue infections. If fluoroquinolones are to be used in these patients, a second drug with predictable anti-anaerobic activity should be included in the regimen. Similarly, fluoroquinolones should be used with caution when infections are known or likely to be caused by methicillin-resistant S. aureus.

Citation: Karchmer A. 2003. Treatment of Skin and Soft Tissue Infections, p 311-321. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch19

Highlighted Text: Show | Hide

Full text loading...

References

/content/book/10.1128/9781555817817.chap19

1. Aldridge, K. E.,, D. Ashcraft,, and K. A. Bowman. 1997. Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes. Antimicrob. Agents Chemother. 41: 484– 487.

2. Appelbaum, P.C. 1999. Quinolone activity againstanaerobes. Drugs 58( Suppl. 2): 60– 64.

3. Bartlett, J. G.,, T. V. Inglesby,, and L. Borio. 2002. Management of anthrax. Clin. Infect. Dis. 35: 851– 858.

4. Beam, T. R., Jr.,, I. Gutierrez,, S. Powell,, R. Hewitt,, M. Hocko,, M. Brackett,, and M. Craver. 1989. Prospective study of the efficacy and safety of oral and intravenous ciprofloxacin in the treatment of diabetic foot infections. Rev. Infect. Dis. 11( Suppl. 5): S1163– S1163

5. Bell, D. M.,, P. E. Kozarsky,, and D. S. Stephens. 2002. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg. Infect. Dis. 8: 222– 225.

6. Betriu, C.,, M. Gomez,, L. Palau,, A. Sanchez,, and J. J. Picazo. 1999. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents. Antimicrob. Agents Chemother. 43: 2320– 2322.

7. Catchpole, C.,, J. M. Andrews,, J. Woodcock,, and R. Wise. 1994. The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg IV and 750 mg PO. J. Antimicrob. Chemother. 33: 103– 110.

8. Citron, D. M.,, and M. D. Appleman. 1997. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerogic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections. Antimicrob. Agents Chemother. 41: 2312– 2316.

9. Credito, K. L.,, M. R. Jacobs,, and P. C. Appelbaum. 2003. Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents. Antimicrob. Agents Chemother. 47: 1399– 1402.

10. Daniel, R., for The Trovafloxacin Study Group. 1999. Comparison of the efficacy and safety of once-daily oral trovafloxacin and 3-times-daily amoxicillin/clavulanic acid for the treatment of complicated skin and soft-tissue infections. Drugs 58( Suppl. 2): 288– 290.

11. Daniel, R., for The Trovafloxacin Study Group. 1999. Oncedaily oral trovafloxacin in the treatment of diabetic foot infections. Drugs 58( Suppl. 2): 291– 292.

12. Daniel, R., for The Trovafloxacin Study Group. 1999. Trovafloxacin once daily vs. flucloxacillin four times daily in the treatment of uncomplicated skin and skin-structure infections. Drugs 58( Suppl. 2): 293– 294.

13. Doern, G. V.,, R. N. Jones,, M. A. Pfaller,, K. C. Kugler,, and M. L. Beach, for the SENTRY Study Group (North America). 1999. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Diagn. Microbiol. Infect. Dis. 34: 65– 72.

14. Drehobl, M.,, L. Koenig,, M. Barker,, P. St Clair,, and D. Maladorno. 1997. Fleroxacin 400 mg once daily versus ofloxacin 400 mg twice daily in skin and soft tissue infections. Chemotherapy 43: 378– 384.

15. Eliopoulos, G. M. 1999. Activity of newer fluoroquinolones in vitro against gram-positive bacteria. Drugs 58( Suppl. 2): 23– 28.

16. Endtz, H. P.,, J. W. Mouton,, and J. G. den Hollander. 1997. Comparative in vitro activities of trovafloxacin (CP 99,219) against 445 gram-positive isolates from patients with endocarditis and those with other blood stream infections. Antimicrob. Agents Chemother. 41: 1146– 1149.

17. Fass, R. L.,, J. F. Plouffe,, and J. A. Russell. 1989. I ntravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. Am. J. Med. 18( Suppl. D): 153– 157.

18. Fleisher, G. R. 1999. The management of bite wounds. N. Engl. J. Med. 340: 138– 140.

19. Gee, T.,, J. M. Andrews,, J. P. Ashby,, G. Marshall,, and R. Wise. 2001. Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose. J. Antimicrob. Chemother. 47: 431– 434.

20. Gentry, L. O. 1991. Review of quinolones in the treatment of infections of skin and skin structure. J. Antimicrob. Chemother. 28( Suppl. C: 97– 110.

21. Gentry, L. O.,, C. H. Ramirez-Ronda,, E. Rodriguez-Noreiga,, H. Thadepalli,, P. L. del Rosal,, and C. Ramirez. 1989. Oral ciprofloxacin vs. parenteral cefotaxime in treatment of difficult skin and skin structure infections: a multicenter trial. Arch. Intern. Med. 149: 2579– 2583.

22. Gentry, L. O.,, G. Rodriguez-Gomez,, B. J. Zeluff,, A. Koshdel,, and M. Price. 1989. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. Am. J. Med. 87( Suppl. 6C): 57S– 60S.

23. Gerding, D. N. 1995. Foot infections in diabetic patients: the role of anaerobes. Clin. Infect. Dis. 20( Suppl. 2): S283– S288

24. Goldstein, E. J.,, D. M. Citron,, Y. Warren,, K. Tyrrell,, and C. V. Merriam. 1999. In vitro activity of gemifloxacin (SB265805) against anaerobes. Antimicrob. Agents Chemother. 43: 2231– 2235.

25. Goldstein, E. J. C.,, D. M. Citron,, M. Hudspeth,, S. H. Gerardo,, and C. V. Merriam. 1997. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Antimicrob. Agents Chemother. 41: 1552– 1557.

26. Goldstein, E. J. C.,, D. M. Citron,, M. Hudspeth,, M. Hudspeth,, and C. V. Merriam. 1997. Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates. Antimicrob. Agents Chemother. 41: 1193– 1195.

27. Goldstein, E. J. C.,, D. M. Citron,, C. V. Merriam,, K. Tyrrell,, and Y. Warren. 1999. Activities ofgemifloxacin (SB 265805, LB20304) compared to those of other oral antimicrobial agents against unusual anaerobes. Antimicrob. Agents Chemother. 43: 2726– 2730.

28. Goldstein, E. J. C.,, D. M. Citron,, C. V. Merriam,, K. Tyrrell,, and Y. Warren. 1999. Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections. Antimicrob. Agents Chemother. 43: 1475– 1479.

29. Goldstein, E.J. C.,, D. M. Citron,, C. V. Merriam,, K. L. Tyrrell,, and H. Fernandez. 2002. In vitro activities of the des-fluoro(6) quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. Antimicrob. Agents Chemother. 46: 866– 870.

30. Goldstein, E. J. C. 1996. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. Clin. Infect. Dis. 23( Suppl. 1): S25– S30.

31. Hecht, D. W.,, and J. R. Osmolski. 2003. Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates. Antimicrob. Agents Chemother. 47: 910– 916.

32. Hecht, D. W.,, and H. M. Wexler. 1996. In vitro susceptibility of anaerobes to quinolones in the United States. Clin. Infect. Dis. 23( Suppl. 1): S2– S8

33. Hooper, D. C. 2000. New uses for new and old quinolones and the challenge of resistance. Clin. Infect. Dis. 30: 243– 254.

34. Johnson, J. H.,, M. A. Cooper,, J. M. Andrews,, and R. Wise. 1992. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob. Agents Chemother. 36: 2444– 2446.

35. Johnson, S.,, F. Lebahn,, L. P. Peterson,, and D. N. Gerding. 1995. Use of an anaerobic collection and transport swab device to recover anaerobic bacteria from infected foot ulcers in diabetics. Clin. Infect. Dis. 20( Suppl. 2): S289– S290.

36. Jones, M. E.,, M. R. Visser,, M. Klootwijk,, P. Heisig,, J. Verhoef,, and F. J. Schmitz. 1999. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacinresistant and -susceptible Staphylococcus aureus strains. Antimicrob. Agents Chemother. 43: 421– 423.

37. Jones, R. N.,, M. L. Beach,, M. A. Pfaller,, and G. V. Doera. 1998. Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America. Diagn. Microbiol. Infect. Dis. 32: 247– 252.

38. Karchmer, A. W.,, and G. W. Gibbons,. 1994. Foot infections in diabetes: evaluation and management, p. 1– 22. In J. S. Remington, and M. N. Swartz (ed.), Current Clinical Topics in Infectious Diseases. Black well Scientific Publications, Boston, Mass.

39. King, A.,, J. May,, G. French,, and I. Phillips. 2000. Comparative in vitro activity of gemifloxacin. J. Antimicrob. Chemother. 45( Suppl. S1): 1– 12.

40. Kirby, J. T.,, A. H. Mutnick,, R. N. Jones,, D. J. Biedenbach,, and M. A. Pfaller, for the SENTRY Participants Group. 2002. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program ( 2000 ). Diagn. Microbiol. Infect. Dis. 43: 303– 309.

41. Lipsky, B. A.,, P. D. Baker,, G. C. Landon,, and R. Fernau. 1997. Antibiotic therapy for diabetic foot infections: Comparison of two parenteral-to-oral regimens. Clin. Infect. Dis. 24: 643– 648.

42. Lipsky, B. A.,, R. E. Pecoraro,, S. A. Larson,, M. E. Hanley,, and J . H. Ahroni. 1990. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch. Intern. Med. 150: 790– 797.

43. Lowe, M. N.,, and H. M. Lamb. 2000. Gemifloxacin. Drugs 59: 1137– 1147.

44. Malanoski, G. J.,, G. W. Gibbons,, J. S. Chrzan,, E. Levin,, and A. W. Karchmer. 1995. Fleroxacin plus clindamycin in the treatment of limb-threatening foot infections in diabetic patients. Clin. Drug Invest. 9( Suppl. 1): 30– 35.

45. Muller, M.,, H. Stab,, M. Brunner,, J. G. Moller,, E. Lackner,, and H. G. Eichler. 1999. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob. Agents Chemother. 43: 2345– 2349.

46. Neldner, K. H. 1991. Double-blind randomized study of oral temafloxacin and cefadroxil in patients with mild to moderately severe bacterial skin infections. Am. J. Med. 91( Suppl. 6A): 111S– 114S.

47. Nichols, R. L.,, J. W. Smith,, L. O. Gentry,, J. Gezon,, T. Campbell,, and R. R. Williams. 1997. Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections. South. Med. J. 90: 1193– 1200.

48. Nicodemo, A. C.,, J. A. Robledo,, A. Jasovich,, and W. Neto. 1998. A multicenter, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int. J. Clin. Pract. 52: 69– 74.

49. Nord, C. E. 1996. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria. Clin. Infect. Dis. 23( Suppl. 1): S15– S18

50. Parrish, L. C.,, and D. L. Jungkind. 1993. Systemic antimicrobialtherapy for skin and skin structure infections: comparison of fleroxacin and ceftazidime. Am. J. Med. 94( Suppl. 3A): 166S– 173S.

51. Parrish, L. C.,, H. B. Routh,, B. Miskin,, J. Fidelholtz,, P. Werschler,, A. Heyd,, D. Haverstock,, and D. Church. 2000. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int. J. Clin. Pract. 54: 497– 503.

52. Peterson, L. R.,, L. M. Lissack,, K. Canter,, C. E. Fasching,, C. Clabots,, and D. N. Gerding. 1989. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am. J. Med. 86: 801– 808.

53. Pong, A.,, K. S. Thomson,, E. S. Moland,, S. A. Chartrand,, and C. C. Sanders. 1999. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin. J. Antimicrob. Chemother. 44: 621– 627.

54. Powers, R. D.,, R. Schwartz,, R. M. Snow,, and D. R. Yarbrough, HI. 1991. Ofloxacin versus cephalexin in the treatment of skin, skin structure, and soft-tissue infections in adults. Clin. Ther. 13: 727– 736.

55. Siami, G.,, N. Christou,, I. Eiseman,, and K. J. Tack, for The Clinafloxacin Severe Skin and Soft Tissue Infections Study Group. 2001. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob. Agents Chemother. 45: 525– 531.

56. Swartz, M. N. 2001. Recognition and management of anthrax: an update. N. Engl. J. Med. 345: 1621– 1626.

57. Talan, D. A.,, D. M. Citron,, F. M. Abrahamian,, G. J. Moran,, and E. J. C. Goldstein, for The Emergency Medicine Animal Bite Infection Study Group. 1999. Bacteriologic analysis of infected dog and cat bites. N. Engl. J. Med. 340: 85– 92.

58. Tarshis, G. A.,, B. M. Miskin,, T. M. Jones,, J. Champlin,, K. J. Wingert,, J. D. Breen,, and M. J. Brown. 2001. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob. Agents Chemother. 45: 2358– 2362.

59. Tassler, H. 1993. Comparative efficacy and safety of oral fleroxacin and amoxicillin/clavulanate potassium in skin and soft tissue infection. Am. J. Med. 94( Suppl. 3A): 159S– 165S.

60. Trampuz, A.,, M. Wenk,, Z. Rajacic,, and W. Zimmerli. 2000. Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid. Antimicrob. Agents Chemother. 44: 1352– 1355.

61. Wexler, H. M.,, E. Molitoris,, D. Molitoris,, and S. M. Finegold. 1998. In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections. Antimicrob. Agents Chemother. 42: 984– 986.

62. Wise, R.,, J. M. Andrews,, J. P. Ashby,, and J. Marshall. 1999. A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose. J. Antimicrob. Chemother. 44: 701– 704.

63. Wise, R.,, J. M. Andrews,, G. Marshall,, and G. Hartman. 1999. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob. Agents Chemother. 43: 1508– 1510.

64. Wise, R.,, T. Gee,, G. Marshall,, and J. M. Andrews. 2002. Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate. Antimicrob. Agents Chemother. 46: 242– 244.

65. Wise, R.,, J. Jones,, I. Das,, and J. M. Andrews. 1998. Pharmacokinetics and inflammatory fluid penetration of clinafloxacin. Antimicrob. Agents Chemother. 42: 428– 430.

66. Wise, R.,, D. Mortiboy,, J. Child,, and J. M. Andrews. 1996. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob. Agents Chemother. 40: 47– 49.

67. Zhao, X.,, W. Eisner,, N. Perl-Rosenthal,, B. Kreiswirth,, and K. Drlica. 2003. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or - resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1023– 1027.

Tables

Treatment of Skin and Soft Tissue Infections

[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555817817.chap19-1,webId=/content/author/10.1128/9781555817817.chap19-1,properties={foaf_givenname=Adolf W., foaf_name=Adolf W. Karchmer, foaf_surname=Karchmer, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555817817.chap19-aff1]]}]]

/content/10.1128/9781555817817.chap19.tab19-1

Table 1

Inflammatory interstitial fluid penetration of selected fluoroquinolones in humans after a single dose a b c d

10.1128/9781555817817/tab19-1_thmb.gif

10.1128/9781555817817/tab19-1.gif

Table 1

Inflammatory interstitial fluid penetration of selected fluoroquinolones in humans after a single dose a b c d

/content/10.1128/9781555817817.chap19.tab19-2

Table 2

Bacterial isolates from skin and soft tissue infections at sites of local injury a

10.1128/9781555817817/tab19-2_thmb.gif

10.1128/9781555817817/tab19-2.gif

Table 2

Bacterial isolates from skin and soft tissue infections at sites of local injury a

/content/10.1128/9781555817817.chap19.tab19-3

Table 3

Bacterial isolates from skin and soft tissue infections in hospitalized patients

10.1128/9781555817817/tab19-3_thmb.gif

10.1128/9781555817817/tab19-3.gif

Table 3

Bacterial isolates from skin and soft tissue infections in hospitalized patients

/content/10.1128/9781555817817.chap19.tab19-4

Table 4

Activity of fluoroquinolones against the principal staphylococci and streptococci that cause skin and soft tissue infection

10.1128/9781555817817/tab19-4_thmb.gif

10.1128/9781555817817/tab19-4.gif

Table 4

Activity of fluoroquinolones against the principal staphylococci and streptococci that cause skin and soft tissue infection

/content/10.1128/9781555817817.chap19.tab19-5

Table 5

Activity of fluoroquinolones against unusual aerobic and anaerobic bacteria isolated from animal and human bite-wound infections

10.1128/9781555817817/tab19-5_thmb.gif

10.1128/9781555817817/tab19-5.gif

Table 5

Activity of fluoroquinolones against unusual aerobic and anaerobic bacteria isolated from animal and human bite-wound infections

/content/10.1128/9781555817817.chap19.tab19-6

Table 6

Comparative randomized trials of fluoroquinolone treatment of uncomplicated skin and soft tissue infections

10.1128/9781555817817/tab19-6_thmb.gif

10.1128/9781555817817/tab19-6.gif

Table 6

Comparative randomized trials of fluoroquinolone treatment of uncomplicated skin and soft tissue infections

/content/10.1128/9781555817817.chap19.tab19-7

Table 7

Comparative randomized trials of fluoroquinolone treatment of complicated skin and soft tissue infection

10.1128/9781555817817/tab19-7_thmb.gif

10.1128/9781555817817/tab19-7.gif

Table 7

Comparative randomized trials of fluoroquinolone treatment of complicated skin and soft tissue infection